Communiqués Lakefront Biotherapeutics NV

Actions

LKFT

BE0003818359

Recherche biotechnologique et médicale

PEA

PEA/PME

Temps réel Euronext Amsterdam 14:10:16 31/08/2026			Varia. 5j.	Varia. 1 janv.
24,74 ^EUR	-1,12 %		-0,08 %	-11,64 %

25/08	Bourse : du rififi chez EssilorLuxottica, des contrats pour Boeing, Eiffage et Exosens
25/08	La montagne accouche d'une souris ?

Communiqués

25/08	Acquisition of Own Shares	GL
24/08	U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus	GL
24/08	Lakefront Receives Transparency Notification from Bank of America	GL
18/08	Acquisition of Own Shares	GL
12/08	Acquisition of Own Shares	GL
10/08	Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update	GL
04/08	Acquisition of Own Shares	GL
28/07	Acquisition of Own Shares	GL
21/07	Acquisition of Own Shares	GL
14/07	Acquisition of Own Shares	GL
13/07	Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi	GL
07/07	Acquisition of Own Shares	GL
30/06	Acquisition of Own Shares	GL
29/06	Lakefront Receives Transparency Notification from Madison Avenue Partners	GL
23/06	Acquisition of Own Shares	GL
17/06	Lakefront Biotherapeutics NV - Acquisition of Own Shares	AQ
16/06	Acquisition of Own Shares	GL
09/06	Lakefront Announces Initiation of €50 Million Stock Repurchase Program	GL
08/06	Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer	GL
04/06	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline	BU
04/06	GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE	GL
26/05	Lakefront Receives Transparency Notification from Bank of America	GL
08/05	Galapagos : Anti-Bribery and Anti-Corruption Policy	PU
06/05	Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update	GL
28/04	Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026	GL